NEW YORK, Dec. 8, 2015 /PRNewswire/ --Ā Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that a review study of treatment of liver cancers with the Delcath Hepatic CHEMOSATĀ® Delivery System (Melphalan/HDS) has been accepted for publication in the Cardiovascular and Interventional Radiology (CVIR), a leading peer-reviewed medical journal.
read more